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Abstract
Nuclear Factor kappa B (NF-kB) is a key mediator of normal immune response but contributes to aggressive cancer cell
phenotypes when aberrantly activated. Here we present evidence that the Inhibitor of Growth 4 (ING4) tumor suppressor
negatively regulates NF-kB in breast cancer. We surveyed primary breast tumor samples for ING4 protein expression using
tissue microarrays and a newly generated antibody. We found that 34% of tumors expressed undetectable to low levels of
the ING4 protein (n = 227). Tumors with low ING4 expression were frequently large in size, high grade, and lymph node
positive, suggesting that down-regulation of ING4 may contribute to breast cancer progression. In the same tumor set, we
found that low ING4 expression correlated with high levels of nuclear phosphorylated p65/RelA (p-p65), an activated form
of NF-kB (p = 0.018). Fifty seven percent of ING4-low/p-p65-high tumors were lymph node-positive, indicating a high
metastatic tendency of these tumors. Conversely, ectopic expression of ING4 inhibited p65/RelA phosphorylation in T47D
and MCF7 breast cancer cells. In addition, ING4 suppressed PMA-induced cell invasion and NF-kB-target gene expression in
T47D cells, indicating that ING4 inhibited NF-kB activity in breast cancer cells. Supportive of the ING4 function in the
regulation of NF-kB-target gene expression, we found that ING4 expression levels inversely correlated with the expression
of NF-kB-target genes in primary breast tumors by analyzing public gene expression datasets. Moreover, low ING4
expression or high expression of the gene signature composed of a subset of ING4-repressed NF-kB-target genes was
associated with reduced disease-free survival in breast cancer patients. Taken together, we conclude that ING4 negatively
regulates NF-kB in breast cancer. Consequently, down-regulation of ING4 leads to activation of NF-kB, contributing to
tumor progression and reduced disease-free patient survival in breast cancer.
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Introduction
Nuclear Factor kappa B (NF-kB) is a central molecule that
mediates immune response by activating gene transcription. The
canonical pathway of NF-kB activation involves receptor signaling
leading to phosphorylation and proteasome-mediated degradation
of Inhibitor of kappa B (IkB), resulting in the release of the NF-kB
subunits from the cytoplasmic IkB complex. The NF-kB subunits,
p65/RelA and p50/NF-kB1, then translocate into the nucleus
where the p65/p50 heterodimers bind to target gene promoter
sequences and activate transcription of a large number of genes
including pro-inflammatory cytokines and chemokines, initiating
the immune response [1,2]. As acute as the NF-kB activation is,
NF-kB is down-regulated by multiple mechanisms after initial
immune response to prevent chronic inflammatory conditions that
could lead to tissue damage and even death [2,3]. In many
cancers, NF-kB is constitutively active, resulting in elevated
expression of NF-kB-target genes that elicit aggressive tumor cell
behaviors including enhanced proliferation, survival, migration,
invasion, metastasis, and therapy resistance [4,5]. Thus, the
molecular alterations that lead to constitutive activation of NF-kB
pose a vital problem relating to cancer etiology and therapy.
In breast cancer, NF-kB activation has been better character-
ized in the human epidermal growth factor receptor 2-positive
(HER2+) molecular subtype. Elevated DNA binding activity of
NF-kB was found predominantly in HER2+ breast tumors [6].
In vitro studies have shown that the HER2/neu receptor could
directly or indirectly activate the kinase cascade that results in the
activation of NF-kB [7–9]. Moreover, inhibition of NF-kB by
various genetic manipulations including the expression of IkBa or
IkB kinase (IKK) mutants attenuated growth of HER2/neu
receptor-initiated mammary tumors in MMTV-ErbB2/neu trans-
genic mice [10–12]. Therefore, these studies corroborated the role
of HER2/neu signaling in NF-kB activation, which in turn
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contributes to the aggressive pathogenesis of HER2+ breast
tumors. More recently, studies have shown that a subset of
estrogen receptor-positive (ER+) breast cancers also contains
elevated NF-kB activity associated with endocrine therapy re-
sistance [13,14]. In addition, a transcriptional synergy between
estrogen receptor and NF-kB has been described, which results in
a gene signature that correlates with chemo-resistance and poor
patient outcome in a subset of ER+ breast cancer [15,16]. While
NF-kB activation in these ER+ breast tumors was partly attributed
to HER2/neu receptor expression, other molecular mechanisms
that lead to NF-kB activation in breast cancer are not well
understood.
Inhibitor of Growth 4 (ING4) is a member of the ING tumor
suppressor family and has been shown to play a role in many
cancer-related cellular processes including cell proliferation,
apoptosis, migration, angiogenesis, contact inhibition, DNA
damage response, and hypoxia [17–24]. Gene deletion or reduced
expression of ING4 has been reported in various cancers including
glioma, breast cancer, head and neck carcinoma, melanoma,
hepatocellular carcinoma, gastric carcinoma, colon cancer, and
lung cancer, implicating a tumor suppressive role of ING4 in
diverse tissue types [20,23,25–32]. ING4 null mice, however, did
not show increased spontaneous tumor formation, suggesting that
ING4 deficiency alone may not be sufficient to initiate tumor-
igenesis [33]. We identified ING4 in a genetic screen for candidate
tumor suppressors that could suppress loss of contact inhibition in
tissue culture [23]. Subsequently, we showed that ING4
suppressed T47D breast cancer cell growth in soft agar and
MYC-initiated mammary hyperplasia in a mouse model, providing
evidence for the ING4 tumor suppressor function in breast cancer
[23,34]. Recently, we reported that 16.5% of breast tumors
harbored an ING4 gene deletion, suggesting a tumor suppressive
role of ING4 in at least a subset of breast cancer [26].
Functionally, ING4 has been characterized as a transcription
regulator with a mechanism involving chromatin remodeling.
ING4 contains a plant homeodomain (PHD) finger motif
conserved among the ING family members and other transcrip-
tion factors [35,36]. ING4 was shown to bind to tri-methylated
histone H3 at lysine 4 (H3K4me3) via the PHD [37,38]. In
addition, ING4 was shown to co-purify with the HBO1/JADE
histone acetyltransferase (HAT) complex, supporting a role of
ING4 in chromatin modification [39,40]. As H3K4me3 and HAT
are generally associated with active transcription, ING4 was
shown to activate gene transcription in response to DNA damage
[17,38]. In glioma and melanoma cancer models, however, ING4
repressed several NF-kB-target genes, thereby attenuating tumor
angiogenesis and growth [20,22,25]. Whether the tumor suppres-
sor function of ING4 involves the repression of NF-kB-target
genes in other cancer types including breast cancer is currently
unknown. Here, we present evidence that ING4 inhibits NF-kB in
breast cancer cells and propose that down-regulation of ING4 is
one of the molecular events that leads to NF-kB activation,
promoting tumor progression and resulting in reduced patient
survival in breast cancer.
Materials and Methods
Recombinant ING4 Protein Purification for Antibody
Generation
DNA fragments encoding the N-terminal (AA 5–147) or C-
terminal (AA 173–249) portion of ING4 were PCR-amplified
using the pMIG-ING4 construct [23] as a template with primer
pairs: 59-ATGTATTTGGAACATTATCTGGAC and 59-
CCCTTTGGAACGAGCACGAGC, 59-ATGCCCTCAGT-
GACCTTTGGC and 59- TTTCTTCTTCCGTTCTTGGGA.
The DNA fragments were cloned into the pET21b bacterial
expression vector (Novagen, Madison, WI) in the coding frame
with a 66HIS epitope-tag at the 39 end of each fragment using
EcoRI and XhoI restriction enzymes (New England BioLabs,
Ipswich, MA). The DNA constructs were used to transform BL21
E. coli (Promega Corporation, Madison, WI). Recombinant
proteins were induced by adding 1 mM IPTG (Promega) and
purified from cell lysate using a Ni-NTA column (Novagen).
Production of Monoclonal Antibodies to ING4
Monoclonal antibodies (mAbs) were generated as previously
described [41] with the following modifications: Peptide ING4–
156 corresponding to the ING4 amino acids 156–178 (CAPK-
TAQKKLKLVRTSPEYGMPS) was synthesized by Sigma-
Genosys (The Woodlands, TX) with an additional cysteine at
the N-terminus. The peptide was coupled to KLH and ovalbumin
using a maleamide conjugation kit (Pierce Thermo Fisher
Scientific, Rockford, IL). Female Balb/c mice (6–8 weeks old)
were injected with an emulsion of 100 mg of recombinant ING4 or
KLH-conjugated peptide ING4-156 with complete Freud’s
adjuvant (Sigma-Aldrich, St. Louis, MO) by intraperitoneal
injection 3 times at 2-week intervals, followed by injections of
75 mg of recombinant protein or peptide in PBS for three
consecutive days. Splenocytes were isolated and fused to the
myeloma cell line P3663Ag8.653 using PEG:DMSO (50:5, %v,
Sigma-Aldrich). Fused cells were seeded in 96-well plates in
DMEM:NCTC-109 (90:10, %v, Invitrogen, Carlsbad, CA) media
supplemented with 20% FBS (Invitrogen), 2 mM Glutamax I
(Invitrogen), 25 mM Hepes, 1X HAT (Sigma-Aldrich), Penicillin/
Streptomycin, and 0.5X Nutridoma-CS (Roche, Branchburg, NJ).
Hybridoma colonies were screened by ELISA and were subcloned
twice by limiting-dilution. Tissue culture supernatants from 6
independent hybridoma clones containing anti-ING4 mAbs
termed BTIM-1 to BTIM-6, were collected and stored with
0.02% sodium azide at 4uC.
Tissue Culture
The ING4 overexpression construct in the pMIG retroviral
vector, pMIG-ING4, has been described previously [23]. The
pMIG-ING4HA construct was generated by cloning the nucleotide
sequence encoding the hemagglutanin (HA) epitope into the 39
end of ING4 via PCR. Cells were transfected with plasmids using
Effectene (Qiagen, Valencia, CA). MCF10A, T47D, and MCF7
cells containing the pMIG vector or pMIG-ING4 were generated
using retroviral infection as described previously [23], followed by
fluorescent activated sorting for green fluorescent protein-positive
cells. Lentiviral particles containing a non-targeting shRNA
construct (shNT) or ING4 knock-down construct (shING4) in
the pLKO.1 vector (Sigma-Aldrich) were used to infect MCF10A
cells. Cells containing shRNA constructs were selected in media
containing 2 mg/ml puromycin (Sigma-Aldrich). The luciferase
reporter plasmid, pGL4.32[luc2P/NF-kB/Hygro], was purchased
from Promega Corporation. Cells containing pGL4.32[luc2P/NF-
kB/Hygro] were selected in media containing 400 mg/ml
hygromycin (Invitrogen). HEK293T cells were grown in DMEM
containing 10% fetal bovine serum (FBS, Thermo-Fisher,
Waltham, MA). T47D and MCF7 cells were grown in RPMI
and MEM:EBSS media (Thermo-Fisher), respectively, supple-
mented with 10% FBS and 10 mg/ml bovine insulin (Sigma-
Aldrich). MCF10A cells were grown in F10:DMEM media
(Thermo-Fisher) supplemented with 10% FBS, 10 mg/ml bovine
insulin, 10 ng/ml human epithelial growth factor (Invitrogen), and
1 mg/ml hydrocortisone (Sigma-Aldrich). Phorbol 12-myristate
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13-acetate (PMA, Sigma-Aldrich) was dissolved in DMSO and
used at a final concentration of 50 ng/ml.
Immunofluorescent Staining and Western Blot Analysis
MCF10A and T47D cells containing various constructs were
plated on chamber slides to 50% confluency, fixed with 4%
paraformaldehyde, and permeabilized with 0.1% Triton X-100.
Cells were immunostained with anti-ING4 antibody (BTIM-4,
1:10 dilution) and Rhodamine Red X-conjugated donkey anti-
mouse secondary antibody (1:200, Jackson Immunoresearch, West
Grove, PA). Cells were additionally stained for nuclei with 49,6-
Diamidino-2-phenylindole (DAPI, Vector Labs, Burlingame, CA)
and visualized using a fluorescent microscope. For Western blot
analyses, anti-ING4 antibody was used in 1:10 dilution. Mono-
clonal antibodies for phospho-p65 (Ser536) (93H1) and p65/RelA
(C22B4) and polyclonal antibodies for IkBa, IKKa, and IKKb,
were purchased from Cell Signaling and used at 1:1,000 dilutions.
Anti-tubulin (DM1A, 1:2,000) and anti-histone H3 (1:1,000)
monoclonal antibodies were purchased from Millipore (Billerica,
MA).
Ethics Statement
Breast tumor samples were obtained from post-retention
formalin-fixed and paraffin-embedded (FFPE) tissue blocks
collected for clinical purposes between the years 1996 and 1999
at Banner Health (Phoenix, AZ). Tumor data regarding tumor
size, histological subtype, grade, and TNM classification were
obtained from de-identified pathology reports. All tissue samples
and pathology report data were compiled adhering to the protocol
(ghostetter05-018/05-0060-06) approved by Western Institutional
Review Board (WIRB) and Banner Health Institutional Review
Board. No informed patient consent was obtained because the
samples had been collected for clinical purposes at the time of
diagnosis and were retrieved post-retention retrospectively. The
patient identity remained anonymous for this study. The In-
stitutional Review Boards approved this waiver of patient consent.
Additional FFPE blocks of breast tumor samples were obtained
from Proteogenex (Culver City, CA), which declared that the
samples were collected with informed patient consent under
Institutional Review Board approved protocols (please see the full
statement at http://www.proteogenex.com/AboutUs/
EthicalIssues.html).
Breast Tumor Tissue Microarray (TMA)
TMAs were constructed by extracting 0.6 mm diameter cores
from the ‘‘donor’’ tumor tissue blocks and transferring tissue cores
into a ‘‘recipient’’ paraffin block using an indexed manual arrayer,
Tissue Arrayer VTA-100 (Veridiam Medical, El Cajon, CA) as
previously described [42]. The TMAs contained 598 tissue
punches from 249 independent tumor samples. Two hundred
thirty and 351 tissue spots on TMAs represented ‘‘double’’ and
‘‘triple punches’’ from 115 and 117 tissue samples, respectively. A
common set of normal breast tissue controls was included on each
TMA.
Immunohistochemistry (IHC)
Immunochemical staining of TMA sections was performed
using BOND-MAX autostainer (Leica Microsystems, Germany).
Antibodies used for IHC were anti-estrogen receptor-alpha (ER-
a) monoclonal (1:200, Novocastra, Newcastle Upon Tyne, UK),
anti-HER2/neu polyclonal (1:300, Novocastra), anti-phospho-
p65 (Ser276) polyclonal (1:40, Cell Signaling, Danvers, MA),
and anti-ING4 monoclonal (1:2, BTIM-4 cell culture superna-
tant). The staining intensity of estrogen receptor (ER) and
HER2 was scored as described previously [43]. All TMA and
whole sections were scored manually by a board certified
pathologist (G.H). An IHC score was assigned to each sample
by averaging the scores of double or triple punch samples. The
percent of evaluable IHC staining on TMAs ranged from
94.5% (ING4) to 99% (p-p65).
Cell Invasion Assay
Invasion assays were performed using 24-well chamber inserts
with a basement membrane protein-coated polycarbonate mem-
brane with 8 mm pores (Cell Biolabs, San Diego, CA). Three
hundred thousand T47D-pMIG or T47D-ING4 cells were seeded
in the upper compartment of the chambers with the medium
containing 50 ng/ml PMA placed in the bottom compartment.
After 48 hours, cells on the opposite side of the membrane were
fixed in cold 70% methanol, stained with Hoechst stain (1:1000,
Invitrogen), and visualized using a fluorescence microscope. Cell
numbers were determined by averaging cell numbers from
a minimum of 4 field images per membrane.
Luciferase Assay
Cells plated in a 24-well dish at 50% confluency were treated
with or without 50 ng/ml PMA for 24 hours. Luciferase activity
in 30 mls of cell lysates was measured using a Steady-Glo
Luciferase Assay System (Promega Corporation) and Victor3
luminometer (Perkin Elmer Life Sciences Products, Boston MA).
Total protein concentration in cell lysates was measured using
the BCA Protein Assay Kit (Pierce Thermo Fisher Scientific).
Luciferase activity was calculated as relative light units per
microgram of protein and normalized to the luc2 gene copy
number integrated into the genome. Luc2 gene copy number
was determined relative to a pGL4.32[luc2P/NF-kB/Hygro]
plasmid DNA standard curve using quantitative PCR (qPCR)
with Fast SYBR Green Master Mix (Applied Biosystems, Foster
City, CA) and two primer pairs specific to the luc2 gene,
(Forward-1 59-TGTGTCCGATTCAGTCATGC-39; Reverse-1
59-TTGCTTAGGTCGTACTTGTCG-39; Forward-2 59-
AGGCTACAAACGCTCTCATC-39; Reverse-2 59- ACA-
TAGTCCACGATCTCCTTC-39).
Reverse Transcription Quantitative PCR (RT-qPCR)
Total RNA was isolated from 56105 cells using the RNeasy
mini kit (Qiagen). Complementary DNA was synthesized from
2 mg of total RNA using the Superscript III First-Strand
Synthesis SuperMix kit with oligo dT primers (Invitrogen).
Quantitative PCR was performed using Taqman Gene Expres-
sion Assays (Applied Biosystems) with FAM-labeled probes for
ING4 (Hs00211773_m1), IL8 (Hs00174103_m1), IL6
(Hs00174131_m1), and PGST2 (COX2) (Hs01573469_m1), and
VIC-labeled probe for GAPDH (4310884E). Reactions were run
using the Applied Biosystems 7900HT Fast Real-Time PCR
system. Data were analyzed by the DDCt-method normalized to
GAPDH. For the qPCR array experiment, T47D-pMIG and
T47D-ING4 cells were treated with 0.1% DMSO (vehicle
control) or 50 ng/ml PMA for 4 hours in full growth media and
RNA was isolated. One mg of total RNA was converted into
cDNA using the RT2 First Strand Kit (SABiosciences-Qiagen).
The qPCR reactions were performed using the 96-well Human
NF-kB signaling targets RT2 Profiler PCR arrays (SABios-
ciences-Qiagen) and data were analyzed using the qPCR array
analysis software from SABiosciences, according to the manu-
facturer’s directions.
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Gene Expression Profile Datasets
The GDS806 [44] and GSE3521/GPL887 [45] datasets
containing gene expression profiles of 60 and 45 primary breast
tumors samples, respectively, were retrieved from Gene Expres-
sion Omnibus (www.ncbi.nih.gov). The Netherlands Cancer
Institute 295 (NKI295) dataset [46] containing gene expression
profiles of 295 primary breast tumor samples was downloaded
from the NKI website (http://bioinformatics.nki.nl/data.php).
Statistical Analysis
Relationship between tumor pathologic features and molecular
markers or between molecular markers was analyzed using
Fisher’s Exact test. A dot plot was used to graph gene expression
levels in each tumor. An unpaired 2-tailed student t-test was used
to determine statistical significance. Kaplan-Meier survival plots
were generated using GraphPad Prism (GraphPad Software, San
Diego, CA). Receiver-operating characteristic (ROC) analysis was
performed to determine the optimal cutoff point for categorization
of ING4-low vs ING4-high expression. The log rank test was used
to calculate statistical significance between the survival curves. P-
values ,0.05 were considered statistically significant.
Results
Monoclonal ING4 Antibody Generation
We have shown that the ING4 gene is deleted in 16.5% of breast
tumors, suggesting a tumor suppressive role in a subset of breast
cancer [26]. In order to evaluate ING4 protein expression in
breast tumors, we first generated a monoclonal antibody that
recognized endogenous ING4 protein with specificity. We
immunized mice with N-terminal (AA 5–147) or C-terminal (AA
173–249) recombinant ING4 protein fragments produced in
bacteria and also with a synthetic peptide corresponding to amino
acids 156–178 of ING4 (Figure 1A diagram and 1B). The N-
terminal ING4 protein injection generated antibodies that
recognized ING4 with specificity, one of which was designated
BTIM-4. The BTIM-4 antibody detected full-length ING4 protein
and ING4 epitope-tagged with hemagglutinin (HA) at the C-
terminal end, overexpressed in 293T cells (Figure 1C). Both
BTIM-4 and anti-HA antibodies detected additional ,26 kDa
and 17 kDa species which may represent degradation products of
overexpressed ING4 (asterisks in Figure 1C). BTIM-4 antibody
did not cross-react with the other ING family member proteins,
ING1, ING2, or ING5, overexpressed in 293T cells, but did detect
the mouse ING4 protein that shares 99% amino acid identity with
the human ING4 protein (data not shown). The C-terminal ING4
protein injection failed to produce antibody specific to ING4 (data
not shown), possibly due to the fact that the C-terminal fragment
contains the PHD finger motif conserved among the ING family
members and other transcription factors [35,36]. The synthetic
peptide injection generated antibodies that recognized over-
expressed ING4 but with high background non-specific bands
(data not shown). The BTIM-4 antibody was characterized further
and referred to as anti-ING4 antibody herein.
Detection of Endogenous ING4 Protein by anti-ING4
Antibody in MCF10A and T47D Cells
We tested whether anti-ING4 antibody detected endogenous
ING4 protein in MCF10A and T47D cells by Western blot.
MCF10A cells are a normal immortalized breast epithelial cell line
with two copies of the ING4 gene. T47D cells are a breast cancer
cell line that contains only one copy of the ING4 gene due to
a defined deletion on chromosome 12 [23,26], providing an
example of ‘‘ING4 low’’ expressing cells. Consistent with this,
T47D cells contained 10-fold less amount of ING4 transcripts
compared to MCF10A cells, normalized to the amount of GAPDH
transcripts in each cell line (Figure S1A). The Western blot analysis
of the cell lines showed that the anti-ING4 antibody detected
a range of ING4 protein expression levels reflective of the relative
mRNA expression in each cell line (Figure 1D).
We next performed immunofluorescent staining of ING4 in the
MCF10A and T47D cell lines using the anti-ING4 antibody. The
results showed nuclear and cytosolic staining of ING4 in both
MCF10A and T47D vector control cells, indicating the antibody
could detect endogenous levels of ING4 (Figure 1E and S1B).
MCF10A and T47D cells overexpressing ING4 showed increased
nuclear staining of ING4, compared to their respective vector
control cells, whereas MCF10A cells with the ING4 knock-down
construct showed diminished ING4 staining compared to the
shNT control (Figure 1E and S1B). We increased the photo-
graphic exposure time for the T47D cell images in order to
visualize the endogenous ING4 protein staining in T47D-pMIG
cells, comparing it to the overexpressed ING4 protein staining in
T47D-ING4 cells (Figure S1B). These results supported the
sensitivity of the antibody in detecting different amounts of the
ING4 protein.
ING4 Immunohistochemical Staining of Breast Tumor
Samples and Correlation with Tumor Features
We proceeded to evaluate ING4 protein expression with the
anti-ING4 antibody in breast tumor samples using immunohisto-
chemistry on tumor tissue microarrays (TMAs). Nuclear staining
of ING4 in tumor samples was scored on a scale of 0 to +3: intense
and uniform nuclear staining was assigned +3 (Figure 2A) and no
staining was assigned 0 (Figure 2C). A normal to slightly
hyperplastic breast tissue section taken from a ductal carcinoma
in situ (DCIS)-only case showed distinct nuclear ING4 staining in
both luminal epithelial and myoepithelial cells within the ductal
structure (Figure 2A inset). Stromal cells also stained for nuclear
ING4 but with less intensity compared to epithelial cells. Normal
breast tissue sections showed identical staining pattern and
intensity for ING4 as the section sample shown in Figure 2A
(data not shown).
We assigned an ING4 IHC score for each tumor sample by
averaging the scores between ‘‘double’’ and ‘‘triple punches’’ on
TMAs and defined less than 1.5 (,1.5) scores as ‘‘low ING4’’ and
greater than or equal to 1.5 ($1.5) scores as ‘‘high ING4.’’ We
observed that 77 tumors among 227 tumors scored ,1.5,
constituting 34% of tumor samples that expressed low levels of
ING4 (Table 1). We then correlated ING4 IHC scores with
pathologic features including histologic subtype, tumor size, BRE
grade, and lymph node status (see Table 1). All 6 DCIS cases
showed +3 score for ING4 (Table 1), indicating that this non-
invasive form of breast cancer expressed ING4 at a level well
detectable by IHC. ING4-low tumors were comparably prevalent
between invasive ductal carcinoma and lobular carcinoma (32% vs
30%; Table 1), suggesting a tumor suppressive role of ING4 in
breast cancers rising from both ductal and lobular structures. Low
ING4 expression was more frequently found in tumors that were
large in size ($2 cm in diameter, 41%), high grade (grade 2 and 3,
40–41%), and lymph node-positive (51%, Table 1; see bold font).
Although we could not assign statistical significance likely due to
the small cohort size, these data showed a consistent trend that
more advanced breast tumors expressed low levels of ING4. These
results suggested that down-regulation of ING4 may contribute to
breast cancer progression.
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Low ING4 Expression Correlates with High Levels of
Phosphorylated p65/RelA in Breast Tumors
We next correlated ING4 protein expression with the molecular
subtype markers, ER and HER2. ING4-low tumors were equally
prevalent between ER+ and ER-negative tumors (35% ER+ vs
29% ER-negative, Figure 2G), as was the case between HER2+ vs
HER2-negative tumors (33% HER2+ vs 34% HER2-negative,
Figure 2G). In addition, we did not observe an increased
frequency of ING4-low tumors in any of the four molecular
subtypes (luminal A, luminal B, basal-like, and HER2; data not
shown). These results suggested that down-regulation of ING4
expression may be an independent event not related to the ER or
HER2 status of the tumor.
We next tested whether low ING4 expression correlated with
NF-kB activation in breast tumors by staining the TMAs with an
antibody against the p65/RelA subunit phosphorylated at the
amino acid residue serine 276 (p-p65/RelA), an activated form of
NF-kB [47,48]. Neither normal breast tissue nor the six DCIS
samples showed nuclear p-p65/RelA IHC staining, suggesting that
p-p65-high represents aberrant NF-kB activation in breast cancer
(data not shown).
We scored nuclear p-p65/RelA staining on a scale of 0 to +3
(Figure 2B, D, F), averaged the scores between double and triple
punches of each sample, and defined ,1.5 scores as ‘‘p-p65-low’’
and $1.5 scores as ‘‘p-p65-high.’’ We then evaluated the
relationship between p-p65/RelA and ING4 expression in breast
tumor samples and found that 47% of p-p65-high tumors
expressed low levels of ING4, compared to 29% of p-p65-low
tumors (p = 0.018, Figure 2G). Two examples of the tumors that
showed low ING4 and high p-p65 levels are shown in Figure 2C–
F. These data indicated a statistically significant correlation
between low ING4 and high p-p65 levels. Furthermore, we found
that ING4-low/p-p65-high tumors were more frequently lymph
node-positive (57%), compared to tumors with the other expres-
sion level makeups (27–39%, Table 2). These results suggested that
phospho-activation of NF-kB may contribute to the high
metastatic tendency of ING4-low tumors. Together, these results
suggested that down-regulation of ING4 may foster phospho-
activation of p65/RelA, resulting in aggressive breast cancer.
ING4 Inhibits p65/RelA Phosphorylation in T47D and
MCF7 Cells
We tested whether ING4 protein expression levels affected
phosphorylation of p65/RelA in breast cancer cell lines in vitro. We
overexpressed ING4 in T47D and MCF7 breast cancer cells,
treated cells with PMA to induce phosphorylation and nuclear
localization of p65/RelA, and blotted for p-p65/RelA (Ser536),
another activated form of p65/RelA [49,50]. We could not assess
Figure 1. Generation and characterization of a monoclonal anti-ING4 antibody. (A) Schematic diagram of ING4 protein containing
a nuclear localization signal (NLS) and a plant homeodomain (PHD). Stick figures represent the ING4 fragments that were used to immunize mice. (B)
N-terminal (AA 5–147) and C-terminal (AA 173–249) recombinant fragments of ING4 purified from bacteria visualized by SDS-PAGE gel stained with
Coomassie Blue. (C) Detection of ING4 and HA-epitope tagged ING4 overexpressed in 293T cells by Western blot using BTIM-4 and anti-HA
monoclonal antibody. * denotes smaller ING4-derived protein species recognized by the antibody. (D) Western blot analysis of ING4 protein
expression using BTIM-4 antibody in MCF10A breast epithelial cells and T47D breast cancer cells containing pMIG (the vector control), ING4 (ING4
overexpression), shNT (non-targeting shRNA control), or shING4 (shRNA targeting ING4). Tubulin antibody was used as a loading control. (E) MCF10A
cells transduced with pMIG (the vector control), ING4 (ING4 overexpression), shNT (non-targeting shRNA control), or shING4 (shRNA targeting ING4),
and T47D cells transduced with pMIG (the vector control) or ING4 (ING4 overexpression) were immunostained with BTIM-4 anti-ING4 antibody (red)
and visualized using fluorescent microscopy. 49,6-Diamidino-2-phenylindole (DAPI) was used to stain individual cell nuclei (blue). White scale bars
represent 100 mm.
doi:10.1371/journal.pone.0046823.g001
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the levels of p-p65/RelA (Ser276) by Western blot because the
antibody was not suitable for Western blot analysis. On the other
hand, the antibody against p-p65/RelA (Ser536) was not suitable
for the IHC application. Thus, we used both forms of p-p65/RelA
as the NF-kB activation markers, as was used in a previous study
[48]. The Western blot results showed that the amounts of total
p65/RelA protein in the cytosolic and nuclear fraction were
comparable between the vector control and ING4 overexpressing
cells (Figure 3A–B). These data indicated that ING4 over-
expression did not affect the expression of p65/RelA or interfere
with the nuclear localization of p65/RelA upon PMA activation.
However, ING4 overexpressing cells contained measurably less p-
p65/RelA (Ser536) in both cytosolic and nuclear fractions (2- to 5-
fold), indicating that phosphorylation of p65/RelA at the amino
acid residue serine 536 was inhibited by ING4 overexpression in
T47D and MCF7 breast cancer cells (Figure 3A–B). These results
were consistent with our observation in breast tumors by IHC that
ING4 expression levels inversely correlated with phospho-activa-
tion of p65/RelA.
In mouse macrophages, ING4 was shown to positively regulate
expression of the NFKBIA gene that encodes Inhibitor of kappa B
alpha (IkBa), thereby inhibiting NF-kB activation [33]. Therefore,
we examined whether ING4 overexpression affected IkBa
expression and found that the protein levels of IkBa were
comparable between T47D-pMIG and T47D-ING4 cells
(Figure 3A bottom panel), indicating that the mechanism of
p65/RelA phosphorylation inhibition by ING4 may not involve
the regulation of IkBa expression.
ING4 Attenuates NF-kB-mediated Cell Invasion
We tested whether ING4 affected NF-kB-mediated cell invasion
utilizing an invasion chamber assay. The results showed that ING4
overexpression attenuated PMA-induced cell invasion of T47D
cells by more than 2-fold (Figure 3C) indicating that ING4
inhibited NF-kB-mediated cell invasion. These results suggested
that breast tumors with low ING4 expression may be more
Figure 2. Inverse correlation between ING4 and p-p65/RelA
(Ser276) antibody staining in breast tumor samples. (A,B)
Hyperplastic breast tissue with moderate atypia from a ductal
carcinoma in situ case, showing ING4 score +3 and p-p65 score 0.
Inset is a higher magnification image of the region showing ING4
staining in luminal and basal epithelial cells and in stroma cells. (C,D)
Invasive ductal carcinoma with ING4 score 0 and p-p65 score +2. (E,F)
Grade 3 invasive ductal carcinoma with ING4 score +1 and p-p65 score
+3. (bars, 100 mm). (G) Low ING4 expression is more prevalent in the
tumors that express high levels of p-p65. Number of ING4-low (solid
bars, IHC score ,1.5) and ING4-high (slanted-line bars, IHC score $1.5)
tumors, presented as a percentage of total number of tumors in each
subgroup. Total (n = 227, 77 ING4-low, 150 ING4-high), ER+ (n = 156, 55
ING4-low, 101 ING4-high), ER2 (n = 63, 18 ING4-low, 45 ING4-high),
HER2- (n = 197, 67 ING4-low, 130 ING4-high), HER2+ (n = 27, 9 ING4-low,
18 ING4-high), p-p65-low (n= 166, 48 ING4-low, 118 ING4-high), and p-
p65-high (n = 62, 29 ING4-low, 33 ING4-high). P values were determined
by Fisher’s Exact test.
doi:10.1371/journal.pone.0046823.g002
Table 1. Tumors with low ING4 protein staining frequently
have advanced tumor features.
Pathologic
feature Subcategory ING4,1.5 ING4$1.5 p
77 (34%) 150 (66%)
Histologic subtype DCIS* 0 6 (100%) 2
IDC{ 51 (32%) 108 (68%) 1
ILC{ 6 (30%) 14 (70%)
Size (diameter) ,2.0 cm 8 (28%) 21 (72%) 0.207
$2.0 cm 47 (41%) 68 (59%)
BRE grade1 Grade 1 8 (27%) 20 (71%) 0.284
Grade 2 29 (40%) 43 (60%)
Grade 3 17 (41%) 25 (59%)
Lymph node status N0 23 (35%) 43 (65%) 0.143
. N0 19 (51%) 18 (49%)
*DCIS, ductal cell carcinoma in situ;
{IDC, invasive ductal carcinoma;
{ILC, invasive lobular carcinoma;
1BRE, Bloom, Richardson, Elston-Ellis grading.
doi:10.1371/journal.pone.0046823.t001
Table 2. Tumors with low ING4 and high p-p65 levels are
frequently lymph node-positive.
Markers Subcategories LN2 LN+
(n = 103) 66 (64%) 37 (36%)
ING4,1.5 p-p65,1.5 (n = 28) 17 (61%) 11 (39%)
p-p65$1.5 (n =14) 6 (43%) 8 (57%)
ING4$1.5 p-p65,1.5 (n = 50) 35 (70%) 15 (30%)
p-p65$1.5 (n = 11) 8 (73%) 3 (27%)
doi:10.1371/journal.pone.0046823.t002
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invasive owing to NF-kB activation, consistent with the data that
ING4-low/p-p65-high tumors were more frequently lymph node
positive (Table 2).
ING4 Attenuates NF-kB-mediated Gene Transcription
In glioblastoma cells and melanoma-associated endothelial cells,
ING4 was shown to repress expression of several NF-kB-target
genes [20,22,25]. In order to determine whether ING4 regulated
NF-kB target gene expression in breast cancer cells as well, we first
used a luciferase reporter construct that contained the NF-kB
response element (NRE) promoter in T47D cells. When the vector
expressing cells, T47D-pMIG, were treated with PMA, the
luciferase activity was induced by 3-fold (Figure 4A). ING4
overexpressing cells, T47D-ING4, however, failed to induce the
luciferase reporter gene expression with PMA treatment, in-
dicating that ING4 repressed NRE-dependent gene transcription
(Figure 4A).
We next evaluated PMA-induced expression of endogenous NF-
kB-target genes, IL6, IL8, and PTGS2 (COX2), in T47D cells using
RT-qPCR. The results showed that in PMA-treated T47D-pMIG
cells, the expression of IL6, IL8, and PTGS2 (COX2), was induced
by 26-, 1070-, and 212-fold, respectively (Figure 4B). In contrast,
in PMA-treated T47D-ING4 cells, IL6, IL8, and PTGS2 (COX2),
were induced by 8-, 35-, and 10-fold, respectively (Figure 4B).
These results indicated that ING4 attenuated the expression of
three endogenous NF-kB-target genes. Taken together with the
luciferase reporter assay results, we concluded that ING4
attenuated NF-kB-mediated gene transcription in T47D breast
cancer cells.
ING4 Represses PMA-induced NF-kB-target Gene
Expression
To evaluate the scope of NF-kB-target genes repressed by
ING4, we compared the expression of 84 NF-kB-target genes in
T47D-pMIG and T47D-ING4 cells with or without PMA
treatment, using a qPCR array (for the complete gene list, see
www.sabiosciences.com). In T47D-pMIG cells, PMA induced 35
NF-kB-target genes by more than 2-fold, ranging from 2- to 489-
fold (Figure 4C and S2). These genes included CXC chemokines
(CXCL1, CXCL2, CXCL10), CC chemokines (CCL2, CCL5, CCL22),
interleukins (IL6, IL8, IL15), and NF-kB signaling molecules
(NFKB1, NFKBIA, RELB). Among the 35 genes, 27 were repressed
by ING4 by more than 2-fold in T47D-ING4 cells (Figure 4C and
S2). These results indicated that more than 75% of PMA-induced
genes were repressed by ING4 at least by 2-fold, suggesting
a general repression mechanism of ING4. In addition, these data
also suggested that breast tumors with low ING4 expression would
express high levels of NF-kB-target genes.
ING4 Expression Inversely Correlates with NF-kB-target
Gene Expression in Primary Breast Tumors
To determine whether ING4-low breast tumors expressed high
levels of the 27 NF-kB-target genes we identified above, we
evaluated the GDS806 dataset [44]. The GDS806 dataset
contained expression information for 25 out of the 27 NF-kB-
target genes that we found repressed by ING4 in the qPCR array
experiment, excluding the C3 and CSF1 genes. We compared the
expression of 25 genes between ING4-low and ING4-high tumors
by assigning an ‘‘ING4/NF-kB gene score’’ to each tumor. The
‘‘ING4/NF-kB gene score’’ of each tumor was calculated by first
either assigning 0 for each NF-kB-target gene if the expression
level was equal to or lower than the median expression of the gene
within the dataset (no activation) or assigning +1 point for each
gene if the expression level was greater than the median expression
of the gene within the dataset (activation), followed by adding the
points of a given set of genes, in this case, 25 genes. The results
showed that ING4-low tumors had a mean ING4/NF-kB gene
Figure 3. Reduced p65/RelA phosphorylation in breast cancer
cells overexpressing ING4. (A) Western blot analysis of T47D cells
expressing pMIG (the vector control) or ING4 (ING4 overexpression) for
ING4, p65, p-p65 (Ser536), and IkBa. Cells were treated with PMA for 0,
15, 30 or 60 minutes prior to cell fractionation. (B) Western blot analysis
of MCF7 cells expressing pMIG (the vector control) or ING4 (ING4
overexpression) for ING4, p65, and p-p65 (Ser536). Cells were treated
with PMA for 60 minutes prior to cell fractionation. Histone H3 and
Tubulin antibodies were used as loading controls for the nuclear and
cytosolic fractions, respectively. (C) ING4 inhibits PMA-induced T47D
cell invasion. Cells that invaded through a basement membrane matrix
were stained with Hoechst dye and visualized under a fluorescent
microscope (picture). Cell numbers were determined by averaging
a minimum of 4 images per experiment from at least 6 independent
experiments. P value was determined by t-test (p = 0.0011).
doi:10.1371/journal.pone.0046823.g003
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score of 14.8, whereas ING4-high tumors had a mean gene score
of 10.2 (p = 0.0002, Figure 4D), indicating that ING4-low breast
tumors expressed high levels of NF-kB-target genes compared to
ING4-high tumors.
We examined an independent breast tumor gene expression
dataset, GSE3521/GPL887, which contained the information on
all 27 NF-kB-target genes repressed by ING4 [45]. We found the
same correlation that ING4-low tumors had higher ING4/NF-kB
gene scores in the GSE3521 data set, validating our observation
with the GDS806 data set (p = 0.037, Figure 4D). These results
demonstrated that ING4 expression levels inversely correlate with
NF-kB-target gene expression in human primary breast tumor
samples, supporting the function of ING4 in the repression of NF-
kB-target genes.
An ING4/NF-kB Gene Signature is Associated with
Reduced Disease-free Survival in Breast Cancer
We next examined the relationship between low ING4
expression and breast tumor recurrence using the GDS806 dataset
[44]. The dataset contained gene expression profiles of primary
tumor samples from patients with ER-positive breast tumors, who
remained disease-free (n = 32, median follow-up of 10 years) or
who recurred (n= 28, median time to recurrence of 4 years) with
adjuvant tamoxifen treatment. We compared the ING4 transcript
levels between the disease-free and recurrent tumor cohorts using
a dot plot and found that primary tumors from patients who later
recurred contained significantly reduced ING4 transcript levels
(p = 0.0181, Figure 5A). We did not find any statistical difference
in the expression levels of the other four ING family members
(ING1, ING2, ING3, and ING5) between disease-free and
recurrent patient tumor samples, highlighting a unique relation-
ship between ING4 expression and tumor recurrence (Figure S3).
We used Receiver-operating characteristic (ROC) analysis to
determine the optimal cut point to group ING4-low vs ING4-high
tumors for the GDS806 dataset and performed Kaplan-Meier
analysis. The results showed that patients with ING4-low tumors
had more than three times the rate of recurrence and significantly
reduced disease-free survival (Figure 5B, HR=3.22, 95% CI
1.24–5.63, log-rank P=0.012), demonstrating that low ING4
expression was associated with reduced disease-free survival in
ER+ breast cancer. We also analyzed an independent dataset,
NKI295 [46], and found that low ING4 expression was associated
Figure 4. ING4 represses NF-kB-target gene expression. (A) ING4 represses expression of a luciferase reporter construct containing an NRE
(NF-kB response element) promoter sequence in T47D cells. (B) ING4 represses expression of endogenous NF-kB-target genes, IL6, IL8, and PTGS2,
evaluated by RT-qPCR. (C) Heat map of 35 NF-kB-target genes induced by PMA in T47D pMIG (vector) cells (red, 2nd row). Twenty-seven of 35 genes
were repressed by ING4 (green, 4th row). Starred genes indicate those previously measured in single RT-qPCR assays. (D) ING4 transcript level
inversely correlates with NF-kB-target gene expression in breast tumors in two independent gene expression profile data sets, GDS806 (n = 60) and
GSE3521 (n = 45). GDS806 contained gene expression data for 25 of the 27 NF-kB-target genes and GSE3521 contained gene expression data for all
27 NF-kB-target genes.
doi:10.1371/journal.pone.0046823.g004
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with reduced disease-free survival (Figure S4, HR=1.55, 95% CI
1.03–2.21, log-rank P= 0.036), validating that low ING4 expres-
sion is associated with reduced disease survival in breast cancer.
We next investigated whether high expression of ING4-
regulated NF-kB-target genes was associated with reduced patient
survival using the GDS806 dataset. We first analyzed the 25 genes
as an ING4/NF-kB gene signature (Figure S2, 27 NF-kB-target
genes repressed by ING4 at least by 2-fold, excluding C3 and CSF1
genes) and evaluated whether the ING4/NF-kB gene scores
correlated with patient survival. The results showed no difference
in disease-free survival between patients with high and low 25-
ING4/NF-kB gene scores (Figure 5C). We next selected a 14 gene
subset of the NF-kB-target genes based on the 4-fold or higher
repression by ING4 (Figure S2) and examined whether the
expression levels of these genes correlated with patient survival.
The results showed that high 14-ING4/NF-kB gene scores were
significantly associated with reduced disease-free survival
(HR=2.23, 95% CI 1.031–4.57, p= 0.0413, Figure 5D), in-
dicating that the high expression of ING4/NF-kB-target genes
recapitulated the association between low ING4 expression and
reduced disease-free survival. Nine individual genes in the 14-gene
subset showed a trend toward a correlation with reduced disease-
free survival (data not shown), suggesting that each gene may
contribute to the association of the collective 14-ING4/NF-kB
gene signature with disease-free survival. These results support the
idea that the tumor suppressor function of ING4 may involve the
repression of a selective NF-kB-target gene set.
Discussion
In a previous study, we reported that the ING4 gene was deleted
in 16.5% of breast tumors [26]. In this study, we showed that 34%
of breast tumors expressed relatively low levels of the ING4
protein, implicating a tumor suppressive role for ING4 in a larger
subset of breast cancer. In addition, breast tumors expressing low
levels of the ING4 protein were frequently high grade and lymph
node positive. Low ING4 expression has been associated with
high-grade tumors and poor prognosis in other cancers including
glioma, melanoma, and hepatocellular carcinoma [20,28,29].
Thus, it appears that down-regulation of ING4 may promote
tumor progression in cancers originating from different tissue
types.
Previously we showed that the ING4 gene deletion was more
prevalent in HER2+ tumors [26]. Considering that gene deletion
may account for one of the mechanisms that result in low protein
expression, we had expected that a higher percentage of HER2+
tumors would express low levels of the ING4 protein. On the
contrary, we found that low ING4 expression was equally
prevalent in HER2+ and HER2-negative tumors, suggesting no
apparent link between the gene deletion rate and low protein
expression. Neither the molecular basis for the elevated ING4 gene
deletion rate in HER2+ breast tumors nor the epigenetic
mechanisms of ING4 down-regulation in breast tumors are
known.
We found that low ING4 expression correlated with high levels
of phosphorylated p65/RelA (p-p65/RelA), an activated form of
NF-kB, in breast tumors, suggesting that down-regulation of ING4
Figure 5. Low ING4 mRNA expression and ING4-regulated NF-kB-target gene signature are associated with reduced disease-free
survival in the GDS806 dataset. (A) Dot plot analysis of ING4 transcript levels in primary breast tumors from patients who remained disease-free
(DF, n = 32) and from those who recurred (REC, n = 28) from the GDS806 dataset (n = 60). (B) Kaplan-Meier analysis of disease-free survival based on
ING4 transcript level from the GDS806 dataset. CI, confidence interval. Kaplan-Meier analysis of disease-free survival based on NF-kB-target gene
signatures (C) 25-gene or (D) 14-gene signature.
doi:10.1371/journal.pone.0046823.g005
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may foster NF-kB activation in breast cancer. Elevated NF-kB
activity has been well documented in HER2+ breast cancer [8].
However, we found the association between low ING4 expression
and high levels of p-p65/RelA in all tumors regardless of the
HER2 status, suggesting that ING4 down-regulation may
represent a mechanism of NF-kB activation independent of
HER2/neu receptor signaling in breast cancer.
Consistent with the inverse relationship between ING4 and p-
p65/RelA levels in breast tumors, over-expression of ING4
resulted in the inhibition of p65/RelA phosphorylation in the
T47D and MCF7 breast cancer cell lines. These data suggest that
ING4 may negatively regulate p65/RelA phosphorylation but the
molecular mechanism is presently unclear. Given the fact that
ING4 is a transcriptional regulator, it is possible that ING4
regulates the expression of kinases or phosphatases involved in
p65/RelA phosphorylation. To date, we found that ING4 did not
alter the expression of PKA, MSK1, and Pim-1 kinases that were
previously shown to phosphorylate p65/RelA at serine 276
[2,47,51], or IKKa and IKKbkinases, previously shown to
phosphorylate p65/RelA at serine 536 [49,50] (data not shown).
Thus, while our data currently show an inverse relationship
between ING4 expression levels and p65/RelA phosphorylation in
vivo and in vitro, it is not clear whether ING4 is directly involved in
the regulation of p65/RelA phosphorylation.
We showed that low ING4 mRNA expression was associated
with reduced disease-free survival in breast cancer patients in two
independent datasets. Our study constitutes the first report of the
clinical consequence of low ING4 expression in breast cancer. It is
of note that ING4-low tumors in the GDS806 dataset had more
than three times the recurrence rate with a Hazard Ratio (HR) of
3.22, while the NKI295 dataset showed 1.55 HR. The precise
reason for this difference is not clear. The GDS806 dataset consists
of the tumor cohorts that were matched for patient age, tumor
size, grade, and metastasis, between the disease-free and recurrent
patient groups [44]. Thus, the efficient stratification of patients by
ING4 expression levels in this dataset may suggest that ING4
expression levels may serve as an independent factor predictive of
aggressive tumors that recur at a faster rate. Another possibility is
that since the patient cohort in the GDS806 dataset was treated
with adjuvant tamoxifen therapy [44], low ING4 expression may
indicate tamoxifen resistance and/or recurrence. This would be
consistent with other studies showing that elevated NF-kB activity
is associated with endocrine therapy resistance [13,14]. However,
whether low ING4 expression is related to tamoxifen resistance
requires further investigation and validation in a larger tamoxifen-
treated cohort. The lower HR value of 1.55 in NKI295 compared
to the one in GDS806 may reflect differences in the patient
demographics between the two cohorts. The NKI295 patient
cohort consists of premenopausal women with the median age of
44 whereas the GDS806 cohort has a median age of 68 [46],
suggesting that low ING4 expression may not stratify younger
patients as effectively. Further investigation is needed to determine
the influence of patient age and menopausal status on the
association between ING4 and disease-free survival.
Our study showed that ING4 repressed the majority of NF-kB-
target genes (.75% of 35 genes). However, only a subset among
the ING4-repressed NF-kB-target genes correlated with poor
patient survival. These results suggested that the tumor suppressor
function of ING4 may be through the repression of a subset of NF-
kB-target genes responsible for aggressive tumor behaviors.
Consistent with this idea, many genes in the ING4/NF-kB gene
signature have been implicated to have a role in aggressive breast
cancer. For example, elevated expression of CXCL10 and its
receptor CXCR3 has been associated with breast cancer
metastasis [52]. CCL2 and CCL5 have been shown to promote
tumor cell migration and invasion [53]. Up-regulation of PTGS2
(COX2) has long been documented in various cancers and
explored as a therapeutic target [54]. In addition, pro-tumorigenic
roles for TNF and IL-6 have also been well established [55]. In our
gene expression dataset analysis, elevated expression of most single
genes in the ING4/NF-kB gene signature did not significantly
correlate with poor patient survival. However, collective high
expression of the gene set correlated with reduced disease-free
survival. Whether this points to a functional cooperation between
the ING4/NF-kB genes resulting in aggressive disease is not clear.
In this study, we surveyed a limited set of 84 NF-kB target genes
using PMA as an agent to active NF-kB. Using other NF-kB
activating agents such as TNF and surveying more extensive NF-
kB-target gene sets may help to refine the ING4/NF-kB gene
signature associated with aggressive breast cancer. In addition, as
inflammation has emerged as a hallmark of cancer in general
[4,56], the ING4/NF-kB gene signature may represent one of the
inflammatory gene signatures associated with tumor progression
and aggressive disease in other cancer types.
We conclude that ING4 negatively regulates NF-kB in breast
cancer. Consequently, down-regulation of ING4 results in NF-kB
activation, leading to disease progression and poor patient
outcome in breast cancer. Our study provides insight into the
tumor suppressor function of ING4 in breast cancer and offers
a molecular basis to explore the ING4/NF-kB pathway as
a potential therapeutic target in order to block disease progression
and improve patient survival.
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